

Docket No.: 029869.00002-US01 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Francis P. Kuhajda et al.

Application No.: 10/520,505

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

Filed: January 7, 2005

For: NOVEL COMPOUNDS, PHARMACEUTICAL

COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Listed on accompanying Form PTO/SB/08a/b are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO/SB/08a/b based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Applicants have checked the appropriate boxes below.

- In This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No statement under 37 C.F.R. § 1.97(e) or fee is required.
- 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
 - □ a. I hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
 - □ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).

3

- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. It is hereby requested that the Information Disclosure Statement be considered. Attached is our Check No. _______ in the amount of \$ _____ in payment of the fee under 37 C.F.R. § 1.17(i).
 - □ a. I hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
 - □ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
- 4. Relevance of the non-English language document(s) is discussed in the present specification.
- 5. The document(s) was/were cited in a corresponding foreign application. An English language version of the foreign search report is attached for the Examiner's information.
- □ 6. A concise explanation of the relevance of the non-English language document(s) appears below:
- The Examiner's attention is directed to co-pending U.S. Patent Application No.
 ________, filed _______, which is directed to related technical subject matter. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The

Examiner is respectfully requested to consider the cited application and the art cited therein during examination.

□ 8. Copies of the documents were cited by or submitted to the Office in Application No.
 _______, filed _______, which is relied upon for an earlier filing date under 35
 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO/SB/08a/b, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 50-0740 referencing Docket No. 029869.00002-US01.

Dated: February 6, 2006

Respectfully submitted,

N. Whitney Wilson

Regis/fration No.: 38,661 COVINGTON & BURLING 1201 Pennsylvania Avenue, N.W. Washington, DC 20004-2401 (202) 662-6000

Attorney for Applicant

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2005. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
escond to a collection of information unless it contains a unit CIMB control combon

Sut	Substitute for form 1449A/B/PTO			Complete if Known		
				Application Number	10/520,505	
11	NFORMATION	1 DI	SCLOSURE	Filing Date	January 7, 2005	
s	TATEMENT	BY /	APPLICANT	First Named Inventor	Francis P. Kuhajda	
				Art Unit	Not Yet Assigned	
	(Use as many sh	eets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attomey Docket Number	029869.00002-US01	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cita No.1	Document Number Number-Kind Coda ² (if known)	Publication Date MM-DD-YYYY	Name of Patentea or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relavant Passages or Relevant Floures Appear	T°
		,				H

**EXAMINED: Intell inference considend, whether on not claim in a conformance with APEP 602. Draw line through claims if not proformance are not considered. Include copy on the form with read commissionable to applicate, "Applicate" an infect on the proformation of the first Code of the Code o

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials		Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
/G.S./CA		CA	DILS, R. et al., Fatty Acid Synthase from Rabbit Mammary Gland, Methods Enzymol., 35:74-83 (1975).			
		СВ	FALO, L.D. et al., Cerulenin Is a Potent Inhibitor of Antigen Processing by Antigen-Presenting Cells, The Journal of Immunology, 139:3918-3923 (1987).			
	Γ	cc	LINN, T.C., Purification and Crystallization of Rat Liver Fatty Acid Synthetase, Archives of Biochemistry and Biophysics, 209(2):613-619 (1981).			
		CD	OMURA, Satoshi, The Antibiotic Cerulenin, a Novel Tool for Biochemistry as an Inhibitor of Fatty Acid Synthesis, Bacteriological Reviews, 40(3):681-697 (1976).			
	Ī	CE	SIMON, S.M. et al., Myristoylation of Proteins in the Yeast Secretory Pathway, The Journal of Biological Chemistry, 267(6):3922-3931 (1992).	Γ		
		CF	TOMODA, H. et al., Evidence for an Essential Role of Long Chain Acyl-CoA Synthetase in Animal Cell Proliferation, The Journal of Biological Chemistry, 266(7):4214-4219 (1991).			
		CG	TRISCARI, J. et al., Changes in Lipid Metabolism in Diet-Induced Obesity, Metabolism, 34(6):580-587 (1985).			
	Ī	СН	WAKIL, S.J., Fatty Acid Synthase, A Proficient Multifunctional Enzyme, Biochemistry, 28(11):4523-4530 (1989).			

*EXAMINER: Initial If refe *EXAMMER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English tanguage Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH, /G.S./

Examiner Signature	/Golam Shameem/	Date Considered	01/09/2009